OS Therapies Inc. Announces $75M ATM Offering with Jefferies

What Happened
OS Therapies Inc. (OSTX) announced on August 21, 2026 that it entered into an Open Market Sale Agreement with Jefferies LLC to conduct an at-the-market (ATM) offering. Under a prospectus supplement to its shelf registration (Form S-3, declared effective Aug 25, 2025), the company may sell up to $75.0 million of common stock from time to time through the Sales Agent. Olshan Frome Wolosky LLP provided a legal opinion on the issuance and sale of the shares.

Key Details

• Agreement date: August 21, 2026; prospectus supplement filed the same day.
• Maximum aggregate offering: up to $75,000,000 of common stock.
• Sales agent: Jefferies LLC; commission: 3.0% of gross proceeds per sale.
• Company to reimburse Jefferies’ counsel fees upon execution up to $100,000 (plus certain ongoing disbursements).
• Company may set selling periods, daily limits and minimum prices; either party may terminate with 10 days’ notice.
• Intended use of proceeds: fund clinical development (ongoing/planned trials), advance R&D programs, and potential complementary acquisitions or investments (no commitments currently).

Why It Matters
This ATM gives OS Therapies a flexible way to raise capital as needed without a fixed follow-on offering. For investors, it means the company can raise funds to support clinical programs and R&D but may issue more shares over time, which can dilute existing shareholders if sales occur. Watch for future placement notices or reported sales under the ATM to see timing and size of any dilution and how proceeds are allocated.